Articles

The majority of patients with metastatic breast cancer receiving treatment with CDK4/6 inhibitors had progression-free survival, behaving similarly when used as first-line therapy or after adjuvant hormonal therapy. Read More ›

For patients with hormone receptor–positive, HER2-negative metastatic breast cancer, response rates for platinum-based chemotherapy were lower than historically observed in patients with triple-negative breast cancer, associated with poor outcomes. Read More ›

In the year 2020, we have witnessed an unprecedented evolution in medicine, as we adjusted our clinical practices, research programs, and educational vehicles to meet the challenges of the COVID-19 pandemic. Read More ›

Personalized starting doses of niraparib based on body weight and platelet count are associated with reductions in thrombocytopenia and other hematologic events. Read More ›

A recent study explores niraparib’s efficacy, safety, and effect on quality of life in compared age-groups. Read More ›

Robotic interval debulking surgery is efficient and safe when treating patients with advanced ovarian cancer who are receiving neoadjuvant chemotherapy. Read More ›

In the phase 2 OVARIO study, median progression-free survival (PFS) has not yet been reached in women with advanced ovarian cancer who are being treated with the combination of niraparib and bevacizumab after response to first-line platinum-based chemotherapy plus bevacizumab. The combination did not appear to cause cumulative toxicities. Read More ›

Researchers evaluated the connections between safety and efficacy and rucaparib pharmacokinetic exposure in patients with recurrent ovarian cancer. Read More ›

Treatment with niraparib improves progression-free survival (PFS) in patients with ovarian cancer regardless of their biomarker status. Read More ›

In patients with newly diagnosed, advanced ovarian cancer and BRCA mutation, olaparib demonstrated a consistently high reduction in the risk for cancer progression and death. Read More ›